Business Context and Reporting Period
This Form 8-K is a current report filed by Trovagene, Inc. (not Cardiff Oncology, Inc.) on April 6, 2018. The registrant is a Delaware corporation headquartered in San Diego, CA. The report discloses a specific corporate event under Item 8.01 (Other Events).
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, or margin data. The only specific financial metric disclosed is a cash outflow related to debt repayment:
- Debt Repayment: Approximately $1,100,000.00 paid to Silicon Valley Bank.
- Debt Status: The payment fully satisfied the outstanding equipment loan.
Material Changes
The material change reported is the complete extinguishment of the company's equipment loan obligation. This transaction reduced the company's debt load to zero regarding this specific instrument and utilized approximately $1.1 million in cash.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on future operations, or discussion of risks and contingencies beyond the specific event of loan repayment. No unusual items were disclosed.
Investor Verification Checklist
- Verify the company name discrepancy: The filing is for Trovagene, Inc., not Cardiff Oncology, Inc.
- Confirm the impact of the $1.1 million cash outflow on the company's remaining liquidity and cash reserves.
- Review subsequent filings to determine if the company has incurred new debt or if this repayment was part of a broader deleveraging strategy.